COMPANION IMMUNOSUPPRESSION WITH AZATHIOPRINE INCREASES THE FREQUENCY OF PERSISTENT RESPONSIVENESS TO PEGLOTICASE IN PATIENTS WITH CHRONIC REFRACTORY GOUT

被引：18
|
作者：
Rainey, H. [1 ]
Baraf, H. S. B. [2 ]
Yeo, A. [1 ]
Lipsky, P. [1 ]
机构：
[1] AMPEL BioSolut, Charlottesville, VA USA
[2] Ctr Rheumatol & Bone Res, Wheaton, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4642
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0410
引用
收藏
页码：438 / 439
页数：2
相关论文
共 50 条
  • [41] PEGLOTICASE TREATMENT SIGNIFICANTLY DECREASES MEAN ARTERIAL BLOOD PRESSURE IN PATIENTS WITH CHRONIC GOUT
    Choi, H.
    Johnson, R.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 659 - 660
  • [42] TREATMENT WITH PEGLOTICASE IMPROVES HEPATIC FIBROSIS ESTIMATED BY FIBROSIS-4 INDEX IN SUBJECTS WITH CHRONIC REFRACTORY GOUT
    Schlesinger, N.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 450 - 450
  • [43] Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout.
    Bahrt, Kenneth M.
    Yeo, Anthony E.
    Howson, Tina L.
    Ottery, Faith D.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S73 - S74
  • [44] DUKE-3: A 15-WEEK OPEN-LABEL TRIAL OF PEGLOTICASE IN REFRACTORY GOUT INCLUDING PATIENTS WITH SOLID ORGAN TRANSPLANT OR PRIOR PEGLOTICASE TREATMENT
    Sundy, J. S.
    Gansen, N.
    Kelly, S.
    Scarlett, E.
    Jaggers, D.
    Hershfield, M. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 446 - 446
  • [45] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Herbert SB Baraf
    Michael A Becker
    Sergio R Gutierrez-Urena
    Edward L Treadwell
    Janitzia Vazquez-Mellado
    Claudia D Rehrig
    Faith D Ottery
    John S Sundy
    Robert A Yood
    Arthritis Research & Therapy, 15
  • [46] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Baraf, Herbert S. B.
    Becker, Michael A.
    Gutierrez-Urena, Sergio R.
    Treadwell, Edward L.
    Vazquez-Mellado, Janitzia
    Rehrig, Claudia D.
    Ottery, Faith D.
    Sundy, John S.
    Yood, Robert A.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
  • [47] Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
    Schlesinger, Naomi
    Yeo, Anthony
    Lipsky, Peter
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [48] LACK OF PREDICTIVE VALUE OF THE NIAID/FAAN CRITERIA TO IDENTIFY SUBJECTS WITH EVIDENCE OF IMMUNE ACTIVATION AFTER RECEIVING PEGLOTICASE FOR CHRONIC REFRACTORY GOUT
    Calabrese, L.
    Kavanaugh, A.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 373 - 373
  • [49] REDUCING IMMUNOGENICITY OF PEGLOTICASE (RECIPE) WITH CONCOMITANT USE OF MYCOPHENOLATE MOFETIL IN PATIENTS WITH REFRACTORY GOUT: A PHASE II RANDOMIZED CONTROLLED TRIAL
    Khanna, P.
    Khanna, D.
    Cutter, G.
    Foster, J.
    Melnick, J.
    Jaafar, S.
    Biggers, S.
    Rahman, F.
    Kuo, H. C.
    Feese, M.
    Saag, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 279 - 280
  • [50] Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares
    Mandell, B. F.
    Fields, T. R.
    Edwards, N. L.
    Yeo, A. E.
    Lipsky, P. E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1085 - 1092
12345